Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Cell Proliferation Process" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
As to increase in number and size, this is achieved through the process of mitosis or cell division. Cells also proliferate and differentiate in order to adapt to a more complex structure and function. CELL PROLIFERATION: "Normally, cell proliferation is a growth process which involves the rapid increase of cells.".
Aurora kinase modulators and method of use
The present invention relates to chemical compounds having a general formula Iwherein A1, A2, C1, C2, D, L1, L2, Z and R1-8 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
Owner:AMGEN INC
Aurora kinase modulators and method of use
The present invention relates to chemical compounds having a general formula I wherein A1, A2, C1, C2, D, L1, L2, Z and R1- are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
Owner:AMGEN INC
Multi-cyclic compounds and method of use
The present invention relates to chemical compounds having a general formula Iwherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.
Owner:AMGEN INC
Method and device for physiotherapy
InactiveUS20060009825A1Reduce inflammationProphylaxis of complicationElectrotherapyMicrowave therapyDamages tissueCell Proliferation Process
This invention relates to biology, veterinary and medicine, and more particularly to methods and devices for physiotherapy with the use of electromagnetic radiation in the ultra-high frequency band. The method consists in that patients are irradiated with electromagnetic microwave field at, at least, one frequency belonging to, at least, one of the 18 frequency ranges. The intensity of radiation at the place of location of the patient does not exceed 3.6 μW / cm2. The device for carrying out the method comprises, at least, one oscillator ensuring the production of electromagnetic radiation in the 18 frequency ranges, both at the main frequencies and at multiple ones. In the result the effect of pain relief is achieved, inflammatory processes are lessened, processes of regeneration of damaged tissues are stimulated, an affected immune status is corrected, the processes of cell proliferation in neoplasms are stabilized, the lysis of necrotic tissue cells occurs.
Owner:CHIRIAEV VIATCHESLAV MIKHAILOVICH +4
Anti-hepatoma stem cell monoclonal antibody and application thereof
InactiveCN103923214AImprove proliferative abilityStrong clonogenicityImmunoglobulins against animals/humansAntibody ingredientsAntigenCell Proliferation Process
The invention discloses an anti-hepatoma stem cell monoclonal antibody which is secreted by a mouse hybridoma cell 4P-120 with the collection number of CGMCC No.8800. Proven by experiments, the monoclonal antibody can be specifically combined with hepatoma cells and is capable of specifically recognizing hepatoma tissues, antigens recognized by the monoclonal antibody are highly expressed in cancer tissues of human hepatoma, but are not expressed or slightly expressed in para-carcinoma tissues, and positive-to-negative differentiation and negative-to-positive defifferentiation exist in a cell multiplication process. Compared with cells with low antigen expression, cells with high antigen expression have higher proliferation capability, clone formation capability, balling capability, scratch transfer capability and invasion transfer capability; and the invention provides a functional monoclonal antibody with an application prospect for treating hepatoma with targeted tumor stem cells, and the monoclonal antibody can be used for preparing medicines for treating hepatoma.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Multi-cyclic compound and method of use
The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.
Owner:AMGEN INC
Aurora kinase modulators and method of use
The present invention relates to chemical compounds having a general formula Iwherein A1, A2, C1, C2, D, L1, L2, Z and R3, R4, R6, R7 and R8 are defined herein, which are capable of modulating Aurora kinase protein activity, thereby influencing various disease states and conditions related to the activities of Aurora kinase proteins. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, processes of preparing compounds of the invention, synthetic intermediates and methods of treatment of conditions related to the activity of Aurora kinase.
Owner:AMGEN INC
Aurora kinase modulators and method of use
ActiveCN101405282AOrganic active ingredientsOrganic chemistryKinase activityCell Proliferation Process
The present invention relates to chemical compounds having a general formula (I) wherein A1, A2, C1, C2, D, L1, L2, Z and R<1-8> are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
Owner:AMGEN INC
Polypeptide for restraining EGF induced tumor cell proliferation through targeted EGFR
ActiveCN109180787APrevent proliferationReduce manufacturing costPeptide/protein ingredientsPeptidesAbnormal tissue growthCell Proliferation Process
The invention relates to a polypeptide for restraining EGF induced tumor cell proliferation through targeted EGFR and belongs to the technical field of biological medicines. According to the invention, a biological active polypeptide TUZG20 is acquired by taking EGF (Epidermal Growth Factor) as a target molecule, elutriating by adopting a phage display technology, taking EGF as an active ingredient, specifically eluting and combining with the phage of the target molecule. The invention proves that the biological active polypeptide TUZG20 is capable of obviously restraining the gastric carcinoma cell proliferation process caused by EGF. The polypeptide provided by the invention has a short sequence, is easy for compounding and large-scale production, is capable of restraining the tumor-promoting action of EGF, has a potential of subsequently developing into anti-cancer drugs and has an important application value at the aspect of research and development of anti-cancer drugs.
Owner:JIANGSU UNIV
Aurora kinase modulators and method of use
The present invention relates to chemical compounds having a general formula Iwherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
Owner:AMGEN INC
C9orfll6 gene capable of regulating liver regeneration, and siRNA (Ribonucleic Acid) interference target spot and application thereof
InactiveCN106754950AOrganic active ingredientsGenetic material ingredientsNucleotideCell Proliferation Process
The invention discloses a c9orf116 gene capable of regulating liver regeneration, and a siRNA (Ribonucleic Acid) interference target spot and application thereof, and belongs to the technical field of molecular biology and biological medicine. The technical scheme key point of the gene is the application of the antagonist of the c9orfll6 gene capable of regulating liver regeneration in preparing a medicine for accelerating liver regeneration. The nucleotide sequence of the c9orfll6 gene is disclosed in SEQ ID NO.1, the antagonist of the c9orf116 gene capable of regulating liver regeneration is the siRNA interference target spot expressed by a specificity interference c9orf116 gene, and the nucleotide sequence of the siRNA interference target spot is disclosed in SEQ ID No.2, SEQ ID NO.3 and SEQ ID NO.4. The c9orfll6 gene disclosed by the invention has a function for accelerating liver proliferation, the gene has an important function in a cell proliferation process, and the gene also has a potential application value on the aspects including cell proliferation and differentiation, tumor treatment, anti-tumor medicine research and development and the like.
Owner:HENAN NORMAL UNIV +1
Method for clustering lasso cluster characteristics based on network analysis
InactiveCN105335626AEasy to buildGood for displaying resultsBiostatisticsSpecial data processing applicationsDiseaseData set
The invention discloses a method for clustering lasso cluster characteristics based on network analysis, which is mainly used for solving the clustering of related expressed genes in bioengineering and establishing a lasso cluster model by using the method. The method comprises the steps of firstly, dividing experimental data into a positive data set and a negative data set, and respectively establishing a weighting co-expression gene network (adjacent matrix) corresponding to the positive data set or the negative data set; secondly, determining important network modules respectively corresponding to a positive sample and a negative sample; thirdly, simplifying a positive sample network module by utilizing a negative sample network module according to the experiment background; finally, clustering the characteristics according to the simplified positive sample network module, and establishing a lasso cluster and a promotion model of the lasso cluster according to the clustering. According to the method disclosed by the invention, the characteristic clustering of the lasso cluster is successfully and organically combined with module selection of network analysis, the operation is easy, the clustering method can be applied to screening of related genes in liver regenerative cell proliferation, and the method has an important application value in simulating a cell proliferation process of complicated diseases such as liver cirrhosis and cancer and screening new drugs.
Owner:HENAN NORMAL UNIV
Culture method for Schwann cells
ActiveCN107513519AHigh yieldHigh purityCulture processNervous system cellsCell Proliferation ProcessCell culture media
The invention discloses a culture method for Schwann cells. The culture method comprises the following steps: S1, culturing mononuclear cells in umbilical cord blood by virtue of an MSCs culture medium to obtain P1 generation umbilical cord blood MSCs; S2, culturing the P1 generation umbilical cord blood MSCs by virtue of a neural sphere culture medium, and harvesting P3 generation neural spheres; and S3, culturing the P3 generation neural spheres by virtue of a Schwann cell culture medium, so that the Schwann cells are obtained. The culture method disclosed by the invention has the beneficial effects that the Schwann cells sourced from umbilical cord blood MSCs are cultured by virtue of a nestin+ neural sphere stage; and formation of the neural spheres is induced by adopting the P1 generation umbilical cord blood MSCs, and neural sphere formation rate reaches up to 41%. The invention also provides a specific neural sphere culture medium, the umbilical cord blood MSCs can be sufficiently induced to be formed into nestin+ neural spheres; and a specific culture scheme that nestin+ neural precursor cells are differentiated into the Schwann cells is provided, adherence and migration of the nestin+ neural precursor cells can be obviously promoted, and agglomeration and multilayer growth in a cell proliferation process are prevented.
Owner:北京再生生物科技研究院有限公司
KIF18A inhibitors
Owner:AMGEN INC
Serum-free medium for stem cells
PendingCN109593717AImprove proliferation efficiencyIncrease the number ofCulture processBlood/immune system cellsAntigenCell Proliferation Process
The invention discloses a serum-free medium for stem cells. The serum-free medium comprises a basic medium, an additive and a cytokine combination, wherein in terms of the volume of the basic medium as reference, the additive comprises transferrin in a volume ratio of 5%-10%, insulin with concentration of 5-15 mg / L, 2-4 mM of L-glutamine, growth factors with concentration of 5-15 ng / mL, BMP-5 antibody with concentration of 0.05-0.25 ng / mL, 2-4 mM of a lipid complex and trace elements with concentration of 1-5 mg / L. The serum-free animal-derived components are adopted, so that interference of many uncertain substances (such as different antigens, antibodies, hormone and cytokines) contained in serum on in-vitro expansion survival rate and the cell proliferation process of hematopoietic stemcells is eliminated, the proliferation efficiency is increased, the quantity of high-activity hematopoietic stem cells is increased, use types and adding content of the cytokines in the in-vitro expansion process of the hematopoietic stem cells are adjusted, then the activity of the hematopoietic stem cells in in-vitro expansion is improved, and death rate of the cells can be reduced.
Owner:广州和能生物科技有限公司
Kif18a inhibitors
ActiveUS20200239441A1Small sizeGood metabolic stabilityOrganic active ingredientsOrganic chemistryDiseaseCell Proliferation Process
Compounds of formula (I):as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Owner:AMGEN INC
A method for detecting the immunosuppressive function of regulatory T cells
InactiveCN102288587AThere is no security riskExtension of timeMicrobiological testing/measurementFluorescence/phosphorescenceRegulatory T cellPhosphate
The present invention relates to a method for detecting the immunosuppressive function of regulatory T cells, wherein the steps of the method include: purifying CD4+T cells and washing with PBS phosphate buffer; solution; add an equal volume of CFSE hydroxyfluorescein diacetate succinimide lipid, preheat PBS phosphate buffer 5 μM, the final concentration of CFSE hydroxyfluorescein diacetate succinimide lipid is 2.5 μM; incubate at room temperature 2 minutes; add an equal volume of fetal calf serum, incubate at room temperature for 1 minute; wash the complete medium 3 times, recount, add to a 96-well plate for 5 days; beneficial effects of the present invention: safe, and the labeled fluorescence can be maintained for several days Weekly; can track the process of cell division and proliferation in vivo; high correlation; specific tracking operation is simple and reliable; stable, objective results, cost-effective, and high efficiency.
Owner:顾鹏
Pyridine derivatives as KIF18A inhibitors
Amide compounds of formula (I) as defined herein: and synthetic intermediates thereof, which are capable of modulating the KIF18A protein, thereby affecting the cell cycle and cell proliferation processes to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.
Owner:AMGEN INC
Kif18a inhibitors
The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Owner:AMGEN INC
Combination compositions and methods of treatment
ActiveUS9492434B2Avoid inactivationEasy to manageOrganic active ingredientsOrganic chemistryDiseaseCell Proliferation Process
The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating cellular proliferation processes, and methods of treating disease, disorders, and symptoms thereof.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
KIF18A inhibitors
Provided are compounds of formula (I) as defined herein, and synthetic intermediates thereof, which are capable of modulating the KIF18A protein, thereby affecting the cell cycle and cell proliferation processes to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.
Owner:AMGEN INC
Aurora kinase modulators and methods of use
The present invention relates to chemical compounds having a general formula Iwherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.
Owner:AMGEN INC
KIF18A inhibitors
ActiveUS11236069B2Small sizeGood metabolic stabilityOrganic active ingredientsOrganic chemistryDiseaseCell Proliferation Process
Owner:AMGEN INC
Kif18a inhibitors
The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Owner:AMGEN INC
Kif18a inhibitors
Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Owner:AMGEN INC
Aurora kinase modulators and method of use
Owner:AMGEN INC
Combination compositions and methods of treatment
ActiveUS20140323450A1Avoid inactivationEasy to manageOrganic active ingredientsBiocideDiseaseCell Proliferation Process
The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating cellular proliferation processes, and methods of treating disease, disorders, and symptoms thereof.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Polysaccharide compositions for tissue repair
ActiveUS20200306288A1Apparent advantageOrganic active ingredientsSurgical drugsAutoimmune conditionTissue repair
The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and / or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.
Owner:JOINTHERAPEUTICS SRL
A Grouping Method of Group Lasso Characteristic Based on Network Analysis
InactiveCN105335626BEasy to buildGood for displaying resultsBiostatisticsSpecial data processing applicationsDiseaseData set
Owner:HENAN NORMAL UNIV
Construction method and application of human miR-106b-5p interference fragment
Since the death rate of melanoma is high, by developing a novel molecular therapeutic target for inhibiting cell proliferation of the melanoma, a laboratory basis for clinical treatment of the melanoma can be provided. MicroRNA (micro-RNA, for short, MiRNA) is non-coding micromolecular RNA of which the length is about 22 nucleotides, plays an important role in the cell proliferation process, has the advantages of being high in tissue specificity, not easy to degrade, easy to detect and the like, and is an ideal target of molecular targeted therapy. Therefore, the invention provides a construction method of a human miR-106b-5p (hsa-miR-106b-5p) interference fragment and application of the human miR-106b-5p interference fragment in the cell proliferation of the melanoma, which can provide anew experimental evidence for basic research and clinical treatment of the melanoma. The full name of miR-106b-5p is human micro ribonucleic acid-106b-5`end (hsa-miR-106b-5p), and the former name of the miR-106b-5p is hsa-miR-106b.
Owner:信雅生物科技(苏州)有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com